Клинические проявления и механизмы развития поражения глаз при гемобластозах

В статье рассмотрены различные офтальмологические проявления при гемобластозах. Представлено подробное описание наиболее распространенных вариантов поражения органа зрения при онкогематологических процессах. Рассмотрены их клинические симптомы, а также механизмы развития, связанные как с прямой инфильтрацией лейкоцитами различных структур глаза, происходящей на фоне основного заболевания, так и сопутствующих состояний, таких как нарушение системы гемостаза, анемия и тромбоцитопения, возникающих в результате прогрессирования онкологического заболевания крови. Рассмотрены случаи офтальмологических проявлений гемобластозов, развивающихся на фоне снижения иммунитета, сопутствующего онкологическому заболеванию, либо в результате токсического действия применяемых химиотерапевтических препаратов, радиотерапии и трансплантации костного мозга, а также таргетной терапии.

1. Гематология: национальное руководство. Под ред. О.А. Рукавицына М.: ГЭОТАР-Медиа. 2015; 776 с.

2. Клиническая онкогематология. Руководство для врачей. Под ред. М.А. Волковой. 2-е изд. М.: Медицина. 2007; 1120 с.

3. Руководство по гематологии. Под ред. А.И. Воробьева. 4-е изд. М.: Ньюдиа‑мед. 2007; 1275 с.

4. Копнин Б.П. Cовременные представления о механизмах злокачественного роста: сходства и различия солидных опухолей и лейкозов. Клиническая онкогематология. 2012;5(3):165–185.

5. Macintyre E, Flandrin G. Biological classification of acute leukemias: federalization or centralization? Leukemia. 1995;9:2152–2154.

6. Willman CL. Acute leukemias: a paradigm for the integration of new technologies in diagnosis and classification. Mod Pathol. 1999;12:218–228.

7. Buchan J, McKibbin M, Burton T. The prevalence of ocular disease in chronic lymphocytic leukaemia. Eye. 2003;17:27–30. doi: 10.1038/sj.eye.6700277.

8. Delestre F, Blanche P, Bouayed E, et al. Ophthalmic involvement of chronic lymphocytic leukemia: A systematic review of 123 cases. Survey of Ophthalmology. 2021;66(1):124–131. doi: 10.1016/j.survophthal.2020.05.001.

9. Curto Mlo, Zingone A, Aquaviva A, Bagnulo S, Calculli L, Cristiani L Leukaemic infiltration of the eye: results of therapy in a retrospective multicentric study. Med Pediatr Oncol. 1989;17:134–139.doi: 10.1002/mpo.2950170212.

10. Reddy SC, Jackson N, Menon BS. Ocular Involvement in Leukemia — A Study of 288 Cases. Ophthalmologica. 2003;217:441–445. doi: 10.1159/000073077.

11. Ohkoshi K, Tsiaras WG. Prognostic importance of ophthalmic manifestations in childhood leukaemia. Br J Ophthalmol. 1992;76:651–655. DOI: 10.1136/bjo.76.11.651.

12. Saglio F, Zecca M, Pagliara D. Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP retrospective study. Bone Marrow Transplant. 2020;55:1918–1927. doi: 10.1038/s41409-020-0806-8.

13. Sharma T, Grewal J, Gupta S. Ophthalmic manifestations of acute leukaemias: the ophthalmologist’s role. Eye. 2008;18:663–672. doi: 10.1038/sj.eye.6701308.

14. Russo V, Scott IU, Querques G. Orbital and ocular manifestation of acute childhood leukemia: clinical and statistical analysis of 180 patients. Eur J Ophthalmol. 2008;18(4):619–623. doi: 10.1177/112067210801800420.

15. Cook BEJ, Bartley GB. Acute lymphoblastic leukaemia manifesting in an adult as a conjunctival mass. Am J Ophthalmol. 1997;124:104–105. doi: 10.1016/S0002-9394(14)71651-4.

16. Takahashi Y, Watanabe Anatomy of Secretory Glands in the Eyelid and Conjunctiva. Ophthalmic Plastic and Reconstructive Surgery. 2013;29(3):215–219. doi: 10.1097/IOP.0b013e3182833dee.

17. Lei KI, Liew CT, Lam DS, Chan AT, Wickham NW. Acute monoblastic leukaemia with conjunctival tumours. Clint Once (R Cull Radial). 1995;7:405–406. doi: 10.1016/S0936-6555(05)80018-4.

18. Talcot, KE, Garg RJ, Garg SJ. Ophthalmic manifestations of leukemia. Current Opinion in Ophthalmology. 2016;27(6):545–551. doi: 10.1097/ICU.0000000000000309.

19. Shah SB, Reichstein DA, Lally SE, Shields CL. Persistent bloody tears as the initial manifestation of conjunctival chloroma associated with chronic myelogenous leukemia. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2013;251(3):991–992. doi: 10.1007/s00417-011-1924-1.

20. Marigo FA, Finger PT. Anterior segment tumors: current concepts and innovations. Survey of Ophthalmology. 2003;48(6):569–593. doi: 10.1016/j.survophthal.2003.08.001.

21. Spraul CW, Lang GE, Lang GK. Corneal ulcer in chronic graft-versus-host disease: treatment with collagen shields. Klin Monatsbl Augenheilkd. 1994;205:161–166. doi: 10.1055/S-2008-1045510.

22. Li JY. Herpes zoster ophthalmicus. Current Opinion in Ophthalmology. 2018;29(4):328–333. doi: 10.1136/bjophthalmol-2015-307157.

23. Cheng LL, Kwok AKH, Wat NMS, Neoh EL, Jon HCK, Lam DSC. Graft-vs-hostdisease-associated conjunctival chemosis and central serous chorioretinopathy after bone marrow transplant. American Journal of Ophthalmology. 2002;134(2):293– 295. doi: 10.1016/S0002-9394(02)01464-2.

24. Patel SV, Herman DC, Anderson PM, Al-Zein NJ, Buettner H. Iris and anterior chamber involvement in acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003 Aug;25(8):653-6. doi: 10.1097/00043426-200308000-00015.

25. Pavithran K, Ajithkumar BV, Aruma R. Bilateral retinal detachment in acute myeloid leukaemia. Asian J Ophthalmol. 2003;5:13–14. doi: 10.1016/j.jcjo.2013.09.009.

26. Adaniya A, Bazterrechea P, Trucco JI, Schlaen BA, Kusminsky G, Saravia MJ. Bilateral macular detachment: Choroid as a sanctuary of acute lymphoblastic leukemia. American journal of ophthalmology case reports. 2020;19:100746. doi: 10.1016/j.ajoc.2020.100746.

27. Ayliffe W, Foster CS, Marcoux P. Relapsing acute myeloid leukaemia manifesting as hypopyon uveitis. Am J Ophthalmol. 1995;119:361–364. doi: 10.1016/s0002-9394(14)71181-x.

28. Jankovic M, Conter V, Pretto G, Placa F, D’Incalci M, Masera G. Isolated bilateral anterior chamber eye relapse in a child with acute lymphoblastic leukaemia. Med Pediatr Oncol. 1995;25(2):109–112. doi: 10.1002/mpo.2950250211.

29. MacLean H, Clarke MP, Strong NP, Kernahan J. Primary relapse of acute leukaemia in anterior segment of the eye. Lancet. 1995;346:500. doi: 10.1016/s0140-6736(95)91347-5.

30. Soylu M, Ozdemir G, Anli A. Pediatric uveitis in southern Turkey. Ocul Immunol Inflamm. 1997;5:197–202. doi: 10.3109/09273949709116894.

31. Garrido Colino C, Mateos Gonzalez M, Torres Valdivieso M. Ocular infiltration in the anterior chamber in a female infant with acute non-lymphoblastic leukaemia. Anales Espanoles de Pediatria. 2001;55:69–72. doi: 10.1016/S1695-4033(01)77629-1.

32. Пармон ЯВ, Саакян СВ. Анализ распространенности метастатического поражения хориоидеи. Альманах клинической медицины. 2016;44(5):592–598.

33. Стоюхина АС, Мусаткина ИВ. Диагностика хориоидальных метастазов. Вестник офтальмологии. 2016;132(3):66–81.

34. Wu L, Calderón M, Hernández G, Marbis J, Ramírez V. Bilateral exudative retinal detachment as the first sign of relapsing acute myelogenous leukaemia. Clinical & experimental ophthalmology. 2006;34(6):623–625. doi: 10.1111/j.1442-9071.2006.01291.

35. Alemayehu W, Shamebo M, Bedri A, Mengistu Z. Ocular manifestations of leukaemia in Ethiopians. Ethiop Med J. 1996;34:217–224.

36. Berendschot TT, DeLint PJ, van Norren D. Fundus reflectance—historical and present ideas. Progress in retinal and eye research. 2003;22(2):171–200. doi: 10.1016/s1350-9462(02)00060-5.

37. Reddy SC, Menon BS. A prospective study of ocular manifestations in childhood acute leukaemia. Acta Ophthalmol Scand. 1998;76:700–703. doi: 10.1034/j.1600-0420.1998.760614.x.

38. Zhioua R, Boussen I, Malek I, Ouertani A. Acute lymphoblastic leukaemia and vitreous infiltration. A case study. J Francais Ophtalmol. 2001;24:180–182.

39. Primack JD, Smith ME, Tychsen L. Retinal detachment in a child as the first sign of leukemic relapse. J Pediatr Ophthalmol Strabismus. 1995;32:253–256. doi: 10.3928/0191-3913-19950701-13.

40. Schworm HD, Nasemann JE, Schriever S. Subretinal hypopyon in prolymphocytic leukaemia. Br J Ophthalmol. 1995;79:863–864. doi: 10.1136/bjo.79.9.863.

41. Colombini A, Barzaghi A, Castagneto M, Bovo G, Rossi MR, Rovelli A. Retro-orbital late relapse in a child with leukaemia after allogeneic bone marrow transplantation. Acta Haematol. 1995;94:44–47.

42. Esmaeli B, Medeiros LJ, Myers J. Orbital mass secondary to precursor T-cell acute lymphoblastic leukemia: a rare presentation. Arch Ophthalmol. 2001;119:443–446. doi: 10.1001/archopht.119.3.443.

43. Hsu LY, Jou JR, Tseng HS, Shiue C, Hou PK, Lin KH. Relapse of acute leukemia in childhood presenting as proptosis due to an orbital mass. J Formos Med Assoc. 1997;96:835–838.

44. Huillard O, Bakalian S, Levy C, Desjardins L, Lumbroso-Le Rouic L, Pop S, Sablin MP, Le Tourneau C. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. European Journal of Cancer. 2014;50(3):638–648. doi: 10.1016/j.ejca.2013.10.016.

45. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. Journal of Clinical Oncology. 2007;25(22):3362–3371. doi: 10.1200/JCO.2006.09.6925.

46. Bindiganavile SH, Bhat N, Lee AG, Gombos DS, Al-Zubidi N. Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review. Journal of Immunotherapy and Precision Oncology. 2021;4(1): 6–15.

47. Hager T, Seitz B. Ocular side effects of biological agents in oncology: what should the clinician be aware of? OncoTargets Ther. 2013;7:69–77. doi: 10.2147/OTT.S54606.

48. Fu C, Gombos DS, Lee J. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2017;8:58709– 58727. doi: 10.18632/oncotarget.17634.

49. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol. 2012;30:3277–3286. doi: 10.1200/JCO.2011.41.5851.

50. Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol (Copenh). 2013;91:604–609. doi: 10.1111/j.1755-3768.2012.02518.x.

51. Esmaeli B, Diba R, Ahmadi MA. Periorbital oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec). Eye. 2004;18:760–762. doi: 10.1038/sj.eye.6701315.

52. Esmaeli B, Prieto VG, Butler CE. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95:881– 887. doi: 10.1002/cncr.10729.

53. Radaelli F, Vener C, Ripamonti F. Conjunctival hemorrhagic events associated with imatinib mesylate. Int J Hematol. 2007;86:390–393. doi: 10.1007/BF02983993.

54. DeLuca C, Shenouda-Awad N, Haskes C, Wrzesinski S. Imatinib mesylate (Gleevec) induced unilateral optic disc edema. Optom Vis Sci. 2012;89:e16–e22. doi: 10.1097/ OPX.0b013e318269111d.

55. Napolitano M, Santoro M, Mancuso S. Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate. Clin Case Rep. 2017;5:1573–1575. doi: 10.1002/ccr3.1137.

56. Kwon S-I, Lee D-H, Kim Y-J. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol. 2008;52:331–333. doi: 10.1007/s10384-008-0561-7.

57. Govind Babu K, Attili VSS, Bapsy PP, Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol. 2007;27:43–44. doi: 10.1007/s10792-007-9038-9.

58. Breccia M, Gentilini F, Cannella L. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res. 2008;32:1022–1025. doi: 10.1016/J. LEUKRES. 2007.10.016.

59. Zaloum A, Falet J-PR, Elkrief A, Chalk C. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma. Neurology. 2020;94:322–323. doi: 10.1212/WNL.0000000000008860.

60. Monge KS, Gálvez-Ruiz A, Alvárez-Carrón A, Quijada C, Matheu A. Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol. 2015;29:227–231. doi: 10.1016/j.sjopt.2014.12.004.

61. Kadayifcilar S, Boyacioglu S, Kart H, Gursoy M, Aydin P. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye. 1999;13:241–246. doi: 10.1038/eye.1999.59.

62. Bajaire BJ, Paipilla DF, Arrieta CE, Oudovitchenko E. Mixed vascular occlusion in a patient with interferon-associated retinopathy. Case Rep Ophthalmol. 2011;2:23– 29. doi: 10.1159/000323942.